Allele specific gain-of-function activity of p53 mutants in lung cancer cells

Catherine A. Vaughan, Rebecca Frum, Isabella Pearsall, Shilpa Singh, Brad Windle, William Andrew Yeudall, Swati P. Deb, Sumitra Deb

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53. Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate. Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels. However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells. We have tested their transactivation potential on p53 target gene promoters by performing transient transcriptional assays in the p53-null H1299 lung cancer cell line. Interestingly, while the mutant p53 target promoter Axl was activated by both the mutants, the p21 promoter was activated by p53-R267P and wild-type p53 but not by p53-P278S; showing a clear difference in transcriptional activity between the two mutants. Our results demonstrate allele specificity between GOF p53 mutants and attempt to show that the specificity is dependent on the transactivation property of GOF p53; it also suggests importance of p21 activation in tumor suppression by p53.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume428
Issue number1
DOIs
StatePublished - Nov 9 2012
Externally publishedYes

Fingerprint

Lung Neoplasms
Alleles
Cells
Cell Line
Transcriptional Activation
p53 Genes
Cell growth
Mutant Proteins
Growth
Nude Mice
Tumors
Assays
Genes
Chemical activation
Amino Acids
Mutation
Neoplasms

Keywords

  • Allele
  • In vivo
  • Mutant
  • P53
  • Specificity

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Allele specific gain-of-function activity of p53 mutants in lung cancer cells. / Vaughan, Catherine A.; Frum, Rebecca; Pearsall, Isabella; Singh, Shilpa; Windle, Brad; Yeudall, William Andrew; Deb, Swati P.; Deb, Sumitra.

In: Biochemical and Biophysical Research Communications, Vol. 428, No. 1, 09.11.2012, p. 6-10.

Research output: Contribution to journalArticle

Vaughan, Catherine A. ; Frum, Rebecca ; Pearsall, Isabella ; Singh, Shilpa ; Windle, Brad ; Yeudall, William Andrew ; Deb, Swati P. ; Deb, Sumitra. / Allele specific gain-of-function activity of p53 mutants in lung cancer cells. In: Biochemical and Biophysical Research Communications. 2012 ; Vol. 428, No. 1. pp. 6-10.
@article{c26f81fbb7cc4c3f94588cc9894c7b5e,
title = "Allele specific gain-of-function activity of p53 mutants in lung cancer cells",
abstract = "p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with {"}gain of function{"} (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53. Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate. Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels. However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells. We have tested their transactivation potential on p53 target gene promoters by performing transient transcriptional assays in the p53-null H1299 lung cancer cell line. Interestingly, while the mutant p53 target promoter Axl was activated by both the mutants, the p21 promoter was activated by p53-R267P and wild-type p53 but not by p53-P278S; showing a clear difference in transcriptional activity between the two mutants. Our results demonstrate allele specificity between GOF p53 mutants and attempt to show that the specificity is dependent on the transactivation property of GOF p53; it also suggests importance of p21 activation in tumor suppression by p53.",
keywords = "Allele, In vivo, Mutant, P53, Specificity",
author = "Vaughan, {Catherine A.} and Rebecca Frum and Isabella Pearsall and Shilpa Singh and Brad Windle and Yeudall, {William Andrew} and Deb, {Swati P.} and Sumitra Deb",
year = "2012",
month = "11",
day = "9",
doi = "10.1016/j.bbrc.2012.09.029",
language = "English (US)",
volume = "428",
pages = "6--10",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Allele specific gain-of-function activity of p53 mutants in lung cancer cells

AU - Vaughan, Catherine A.

AU - Frum, Rebecca

AU - Pearsall, Isabella

AU - Singh, Shilpa

AU - Windle, Brad

AU - Yeudall, William Andrew

AU - Deb, Swati P.

AU - Deb, Sumitra

PY - 2012/11/9

Y1 - 2012/11/9

N2 - p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53. Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate. Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels. However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells. We have tested their transactivation potential on p53 target gene promoters by performing transient transcriptional assays in the p53-null H1299 lung cancer cell line. Interestingly, while the mutant p53 target promoter Axl was activated by both the mutants, the p21 promoter was activated by p53-R267P and wild-type p53 but not by p53-P278S; showing a clear difference in transcriptional activity between the two mutants. Our results demonstrate allele specificity between GOF p53 mutants and attempt to show that the specificity is dependent on the transactivation property of GOF p53; it also suggests importance of p21 activation in tumor suppression by p53.

AB - p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53. Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate. Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels. However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells. We have tested their transactivation potential on p53 target gene promoters by performing transient transcriptional assays in the p53-null H1299 lung cancer cell line. Interestingly, while the mutant p53 target promoter Axl was activated by both the mutants, the p21 promoter was activated by p53-R267P and wild-type p53 but not by p53-P278S; showing a clear difference in transcriptional activity between the two mutants. Our results demonstrate allele specificity between GOF p53 mutants and attempt to show that the specificity is dependent on the transactivation property of GOF p53; it also suggests importance of p21 activation in tumor suppression by p53.

KW - Allele

KW - In vivo

KW - Mutant

KW - P53

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=84868359914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868359914&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2012.09.029

DO - 10.1016/j.bbrc.2012.09.029

M3 - Article

VL - 428

SP - 6

EP - 10

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -